Key result
Dilated cardiomyopathy develops in ~17% of titin-truncating variant carriers over median 5.7 years.
Why the study?
Cardiomyopathy guidelines recommend routine screening of at-risk relatives with DCM carrying titin-truncating variants, but the diagnostic yield is low and risk-based stratification could optimize screening intervals and resource allocation.
Can risk-based stratification optimize echocardiographic screening intervals for the development of DCM in at-risk relatives carrying a titin-truncating variant?
Cohort (n=413)
Yes
Can risk-based stratification optimize echocardiographic screening intervals for the development of DCM in at-risk relatives carrying a titin-truncating variant?
An evidence-based, genotype-specific longitudinal screening algorithm integrating age, sex, and echocardiographic findings can safely optimize screening intervals for relatives at risk of TTNtv-related dilated cardiomyopathy.
Supports family screening in DCM; extends penetrance data but leaves optimal protocols open.
BACKGROUND: Cardiomyopathy guidelines recommend routine screening of at-risk relatives with dilated cardiomyopathy (DCM). Titin-truncating variants are the most prevalent cause. However, the diagnostic yield of screening is low. Risk-based stratification could optimize screening intervals and resource allocation. This study aims to develop a safe, evidence-based gene-specific longitudinal screening algorithm for DCM development. METHODS: We included likely pathogenic/pathogenic titin-truncating variant relatives from 7 centers who underwent cardiac screening. Relatives were stratified based on their baseline clinical phenotype: genotype-positive/phenotype-negative (no left ventricular dysfunction and dilatation) or partial DCM (ie, fulfilling only 1 criterion). DCM development predictors were identified based on follow-up data. Risk profiles were established and used to develop a multistate model to create a longitudinal screening algorithm to safely and effectively monitor titin-truncating variant relatives. RESULTS: Among 413 relatives, follow-up data were available in 301 relatives (median follow-up 5.7 years), of whom 24.6% developed left ventricular dysfunction or dilatation and 17.3% developed DCM. In total, 16 relatives (5.3%) experienced a major adverse cardiac event after DCM diagnosis. Based on the identified risk factors, age ≥30 years, male sex, and partial DCM, 3 distinct profiles were established: (1) relatives with partial DCM, (2) females ≥30 years and males, and (3) female relatives <30 years. A screening algorithm was developed, recommending intervals of 1, 3, and 5 years, optimizing the balance between safety and effectiveness. CONCLUSIONS: An evidence-based genotype-specific longitudinal screening algorithm that integrates age, sex, and echocardiographic measurements may improve patient care and improve efficiency of clinical resource allocation.
No takes yet. Share an insight, caveat, or question.
Muller et al. (2026) conducted a cohort in Dilated cardiomyopathy risk in titin-truncating variant carriers (n=413). Baseline clinical phenotype and demographic risk factors (age, sex, partial DCM) was evaluated on Development of left ventricular dysfunction, dilatation, or dilated cardiomyopathy. Among titin-truncating variant carriers, 17.3% developed dilated cardiomyopathy over a median 5.7 years, prompting the creation of a risk-stratified 1-, 3-, and 5-year screening algorithm.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: